AU2009308665B2 - Compositions containing delta-9-THC-amino acid esters and process of preparation - Google Patents

Compositions containing delta-9-THC-amino acid esters and process of preparation Download PDF

Info

Publication number
AU2009308665B2
AU2009308665B2 AU2009308665A AU2009308665A AU2009308665B2 AU 2009308665 B2 AU2009308665 B2 AU 2009308665B2 AU 2009308665 A AU2009308665 A AU 2009308665A AU 2009308665 A AU2009308665 A AU 2009308665A AU 2009308665 B2 AU2009308665 B2 AU 2009308665B2
Authority
AU
Australia
Prior art keywords
amino acid
thc
tetrahydrocannabinol
derivative
dcm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009308665A
Other languages
English (en)
Other versions
AU2009308665A1 (en
Inventor
Mahmoud A. Elsohly
Waseem Gul
Soumyajit Majumdar
Michael A. Repka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Mississippi
Original Assignee
University of Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Mississippi filed Critical University of Mississippi
Publication of AU2009308665A1 publication Critical patent/AU2009308665A1/en
Assigned to THE UNIVERSITY OF MISSISSIPPI reassignment THE UNIVERSITY OF MISSISSIPPI Request for Assignment Assignors: ELSOHLY LABORATORIES, INCORPORATED
Application granted granted Critical
Publication of AU2009308665B2 publication Critical patent/AU2009308665B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B13/00—Accessories or details of general applicability for machines or apparatus for cleaning
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B3/00—Cleaning by methods involving the use or presence of liquid or steam
    • B08B3/02—Cleaning by the force of jets or sprays
    • B08B3/026—Cleaning by making use of hand-held spray guns; Fluid preparations therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B2203/00—Details of cleaning machines or methods involving the use or presence of liquid or steam
    • B08B2203/02—Details of machines or methods for cleaning by the force of jets or sprays
    • B08B2203/0264—Splash guards

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009308665A 2008-10-31 2009-11-02 Compositions containing delta-9-THC-amino acid esters and process of preparation Active AU2009308665B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11016508P 2008-10-31 2008-10-31
US61/110,165 2008-10-31
PCT/US2009/062998 WO2010051541A2 (en) 2008-10-31 2009-11-02 Compositions containing delta-9-thc-amino acid esters and process of preparation

Publications (2)

Publication Number Publication Date
AU2009308665A1 AU2009308665A1 (en) 2010-05-06
AU2009308665B2 true AU2009308665B2 (en) 2015-10-22

Family

ID=42129588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009308665A Active AU2009308665B2 (en) 2008-10-31 2009-11-02 Compositions containing delta-9-THC-amino acid esters and process of preparation

Country Status (10)

Country Link
US (2) US8809261B2 (enExample)
EP (1) EP2352497B1 (enExample)
JP (1) JP5739344B2 (enExample)
AU (1) AU2009308665B2 (enExample)
CA (1) CA2741862C (enExample)
DK (1) DK2352497T3 (enExample)
ES (1) ES2622582T3 (enExample)
HU (1) HUE032158T2 (enExample)
PL (1) PL2352497T3 (enExample)
WO (1) WO2010051541A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US8991402B2 (en) 2007-12-18 2015-03-31 Pax Labs, Inc. Aerosol devices and methods for inhaling a substance and uses thereof
PL2352497T3 (pl) * 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
US10517530B2 (en) 2012-08-28 2019-12-31 Juul Labs, Inc. Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
KR102705152B1 (ko) 2013-05-06 2024-09-09 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 염 제제 및 그 방법
CN111642812A (zh) 2013-06-14 2020-09-11 尤尔实验室有限公司 电子汽化设备中的具有单独的可汽化材料的多个加热元件
KR102957402B1 (ko) 2013-12-05 2026-04-24 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 액제 및 그 방법
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
KR102721939B1 (ko) 2013-12-23 2024-10-25 쥴 랩스, 인크. 기화 디바이스 시스템 및 방법
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
WO2015175979A1 (en) 2014-05-16 2015-11-19 Pax Labs, Inc. Systems and methods for aerosolizing a smokeable material
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
KR20250012730A (ko) 2014-12-05 2025-01-24 쥴 랩스, 인크. 교정된 투여량 제어
AU2016231788A1 (en) * 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
CN105037180B (zh) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 一种双重作用的中枢性镇痛新化合物、制备方法及用途
CA2985332C (en) 2015-05-18 2023-01-03 5071, Inc. Homogenous cannabis compositions and methods of making the same
EP3297617A4 (en) * 2015-05-18 2019-02-20 5071, Inc. HOMOGENEOUS CANNABIC COMPOSITION AND METHOD FOR THE MANUFACTURE THEREOF
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
WO2017132526A1 (en) 2016-01-29 2017-08-03 University Of Mississippi Biologically active cannabidiol analogs
MX377347B (es) 2016-02-11 2025-03-07 Juul Labs Inc Cartucho rellenable de vaporizador y metodo de relleno
MX388616B (es) 2016-02-11 2025-03-20 Juul Labs Inc Cartuchos de fijacion segura para dispositivos vaporizadores
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
EP3442521B1 (en) 2016-04-15 2026-05-20 Sre Wellness Inc Sweeteners and other compositions infused with cannabis
CA3021095A1 (en) 2016-04-15 2017-10-19 Sre Wellness Inc. Method of making cannabis oil hydrophiilic using emulsifiers and related cannabinoid compositions
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
JP2019523228A (ja) * 2016-06-16 2019-08-22 ティーウィノット テクノロジーズ リミテッド カンナビノイドプロドラッグの製造のための方法、薬学的製剤、およびその使用
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
US11660403B2 (en) 2016-09-22 2023-05-30 Juul Labs, Inc. Leak-resistant vaporizer device
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
BR112019006194A2 (pt) 2016-09-28 2019-06-18 Novaliq Gmbh composições que compreendem um ligante de ligação ao receptor de canabinóides
CA3059227A1 (en) 2017-04-05 2018-10-11 University Of Mississippi Isolation of pure cannabinoids from cannabis
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
EP3424493A1 (en) 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
WO2019014631A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
CA3072768C (en) * 2017-08-27 2024-06-11 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019100172A1 (en) * 2017-11-27 2019-05-31 Beleave Inc. Extraction and purification of cannabinoid compounds
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3876907A4 (en) * 2018-11-07 2022-08-10 Columbia Care LLC CANNABINOID SUPPOSITORY FORMULATIONS
US20200254104A1 (en) * 2019-02-11 2020-08-13 John CHANCEY Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disacchride, or monosaccharide
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CA3132861A1 (en) * 2019-03-12 2020-09-17 6th Wave Innovations Corp. Molecularly imprinted polymers for extraction of cannabinoids and uses thereof
EP3952860A1 (en) * 2019-04-09 2022-02-16 Powderpost LLC Methods and compositions for use in treatment of cancer without psychoactive effects
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
JP7702654B2 (ja) 2020-06-30 2025-07-04 リユニオン・ニューロサイエンス、インコーポレイテッド トリプタミンプロドラッグ
IL303034A (en) * 2020-11-06 2023-07-01 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology
US11242328B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
US11242330B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Organic catalyst and method for preparation of aromatic tricyclic pyrans
US11352337B1 (en) * 2021-06-02 2022-06-07 Acid Neutral Alkaline Laboratory Zeolite catalyst and method for preparation of aromatic tricyclic pyrans

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB313977A (en) * 1927-12-21 1929-06-21 British United Shoe Machinery Improvements in or relating to boot or shoe sewing machines or methods of making boots or shoes by the use thereof
US4933363A (en) * 1988-08-16 1990-06-12 Elsohly Mahmoud A Method for effecting systemic delivery of delta-9-tetrahydrocannabinol
WO2008134668A2 (en) * 2007-04-27 2008-11-06 Alexza Pharmaceuticals, Inc. Heat-labile prodrugs
WO2009073633A1 (en) * 2007-11-30 2009-06-11 Alltranz Inc. Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5518709B2 (enExample) * 1970-02-13 1980-05-21
US6040298A (en) * 1992-12-23 2000-03-21 Oclassen Pharmaceuticals, Inc. Methods for treatment with compositions effective against acyclovir-resistant strains of herpes viruses
US5389375A (en) * 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
US6008383A (en) * 1998-10-26 1999-12-28 University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol esters
US20060078955A1 (en) * 2004-10-13 2006-04-13 Lin-Zhi International Method for retrieving delta9-THC from oral fluid
US20080260691A1 (en) 2004-11-02 2008-10-23 New River Pharmaceuticals Inc. Prodrugs of Ribavirin with Improved Hepatic Delivery
EP2046290A4 (en) * 2006-08-04 2011-08-17 Insys Therapeutics Inc AQUEOUS DRONABINOL FORMULATIONS
WO2009026461A2 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US20100303883A1 (en) * 2007-10-17 2010-12-02 Axxia Pharmaceuticals, Llc Polymeric drug delivery systems and thermoplastic extrusion processes for producing such systems
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
PL2352497T3 (pl) * 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB313977A (en) * 1927-12-21 1929-06-21 British United Shoe Machinery Improvements in or relating to boot or shoe sewing machines or methods of making boots or shoes by the use thereof
US4933363A (en) * 1988-08-16 1990-06-12 Elsohly Mahmoud A Method for effecting systemic delivery of delta-9-tetrahydrocannabinol
WO2008134668A2 (en) * 2007-04-27 2008-11-06 Alexza Pharmaceuticals, Inc. Heat-labile prodrugs
WO2009073633A1 (en) * 2007-11-30 2009-06-11 Alltranz Inc. Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELSOHLY, M.A., et al., Pharmacology Biochemistry & Behavior, 1991, vol. 40, pp. 497-502 *
ZITCO, B.A., et al., Science, 1972, vol. 177. pp. 442-444 *

Also Published As

Publication number Publication date
HUE032158T2 (en) 2017-09-28
US9630941B2 (en) 2017-04-25
EP2352497A2 (en) 2011-08-10
WO2010051541A3 (en) 2010-07-08
JP5739344B2 (ja) 2015-06-24
EP2352497A4 (en) 2012-08-01
US20150045282A1 (en) 2015-02-12
EP2352497B1 (en) 2017-02-22
AU2009308665A1 (en) 2010-05-06
CA2741862C (en) 2017-10-17
ES2622582T3 (es) 2017-07-06
WO2010051541A2 (en) 2010-05-06
DK2352497T3 (en) 2017-04-03
US20110275555A1 (en) 2011-11-10
CA2741862A1 (en) 2010-05-06
US8809261B2 (en) 2014-08-19
PL2352497T3 (pl) 2017-08-31
HK1158517A1 (en) 2012-07-20
JP2012507568A (ja) 2012-03-29

Similar Documents

Publication Publication Date Title
CA2741862C (en) Compositions containing delta-9-thc-amino acid esters and process of preparation
AU2013245756B2 (en) Enhanced anti-influenza agents conjugated with anti-inflammatory activity
RU2623426C2 (ru) Способ получения блок-сополимера
BRPI0611435A2 (pt) derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
CN107987081B (zh) 一种二氢卟吩e6衍生物及其药学上可接受的盐、其制备方法和应用
CN101624376B (zh) 取代酰肼类化合物及其应用
CN103387601B (zh) 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
CN103304573B (zh) 石蒜碱类化合物在制备抗肿瘤药物的应用
US20050220753A1 (en) Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them
CN115385875A (zh) 一类紫杉醇衍生物及其制备方法和用途
JP6817956B2 (ja) 新規なグルタミン酸誘導体とブロック共重合体を含有する組成物及びその用途
CN113773259A (zh) 病毒主蛋白酶抑制剂及其制备方法和用途
CN115974849B (zh) 一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用
HK1158517B (en) Process of preparation of delta-9-thc-amino acid esters
ES2861062T3 (es) Procedimiento de purificación de un derivado de benzopirano, forma cristalina del mismo, y procedimiento de preparación de la forma cristalina
US20070072802A1 (en) Peptide nucleic acid based guanidinium compounds
CN117384136A (zh) 一种no供体型抗真菌化合物及其制法和应用
CN110922450B (zh) Psma激活式抗肿瘤前药cpt-x及其制备方法和应用
CN120040321B (zh) 基于疏水标签技术的神经氨酸酶抑制剂及其制备方法、衍生物、药物组合物和应用
HK40086425A (zh) 秋水仙碱衍生物的制备方法及其用途
KR101603317B1 (ko) 케르세틴-아미노산 접합체를 포함하는 항암 및 항생제 내성 억제효능을 보이는 조성물 및 그 방법
CN109422759A (zh) 小分子修饰的紫杉烷类水溶性前药及其药用用途
KR20220068805A (ko) 신규한 글루코스 유도체
WO2024152886A1 (zh) 去唾液酸糖蛋白受体配体与细胞毒素的偶联物及其应用
CN121554428A (zh) 二酮基哌嗪甲基化衍生物及其制备方法和应用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ELSOHLY, MAHMOUD A.; GUL, WASEEM; REPKA, MICHAEL A. AND MAJUMDAR, SOUMYAJIT

PC1 Assignment before grant (sect. 113)

Owner name: THE UNIVERSITY OF MISSISSIPPI

Free format text: FORMER APPLICANT(S): ELSOHLY LABORATORIES, INCORPORATED

FGA Letters patent sealed or granted (standard patent)